about
Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serumPlasma and Liver Hepatitis C Virus Variability in Patients Coinfected with Human Immunodeficiency VirusEstimation of dynamical model parameters taking into account undetectable marker valuesMulticenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load DeterminationHIV-1 tropism and liver fibrosis in HIV-HCV co-infected patientsInterpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limitsPrevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.Multicenter quality control of hepatitis C virus protease inhibitor resistance genotypingCombined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit.A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay.A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS® TaqMan® HCV Test and RealTime HCV Assay.European Multicenter Study on Analytical Performance of DxN Veris System HCV AssayOverlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.Acute hepatitis associated with hepatitis G virus primo-infection in a renal transplant recipient.Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins.Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years).Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study.Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.HIV and HCV co-infection: situation at six French university hospitals in the year 2000.NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.Seven nucleotide changes characteristic of the hepatitis C virus genotype 3 5' untranslated region: correlation with reduced in vitro replication.Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004.Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
P50
Q27472747-1DC4066C-B195-47DD-A6FC-9E01FF8787F1Q27473249-24652402-BE54-4636-891D-808E55F8442DQ27473567-3CE003E1-1615-4A1D-B045-3D00222ADF0AQ27484906-B68AA9D6-F827-49C2-B161-DF074F2BCC8FQ34505231-6C2FEF9E-354C-43AF-8190-E59E3875326EQ34741602-051C9BAF-8DCB-4645-81A3-9F5B4E78B1EFQ35735285-1D96DB93-7290-4C8B-9B8B-508B95D270CFQ35757761-1EF0E27F-E814-4A36-AABF-63DC7B4FD4A4Q36342175-E4AAF2F6-7B56-4056-9F1B-2E2A76516710Q36698116-89A87604-A881-476D-8C79-55EABF6EA976Q36826639-D110D58A-D026-4DCB-A3A9-ACC9D5DC9B11Q38424625-18111321-9E1D-4CFA-A9FD-4E90667A8B60Q38668407-8B2AB83B-9DFE-4D43-A412-799A54C325C2Q38864459-D98A32AF-4AFE-4BF2-A6BC-89492A9E59E5Q40047560-FCC11D9C-B91E-4BF2-99E7-9ED6B0F480A6Q40165802-2F7AD863-39CB-49D7-A0D2-91E06441105DQ40284662-199AFA53-28D8-4532-AE11-0156F56387CBQ40348977-75F252FB-610F-459A-A76C-D3328D2B3AC2Q42672006-E12A2736-DD6A-43A0-9B36-CC3A163F7C89Q42977167-172E6AA5-9F1B-411B-9478-721717D7E534Q42978858-13200715-E4BD-4AD2-97D6-43418437A3E5Q42981457-2B5A6077-EEFD-4D1E-8104-469AE1C770E6Q42987751-1C836033-D2FD-4C70-A08F-571EDB77445BQ42991934-BFEE3E73-5FD1-40E8-87ED-13AC404982EEQ42992084-583EA8D7-D56D-40A8-B0C9-B992494DE857Q42992141-4BB51E9B-3929-4B45-A08D-D1AA0AE0D821Q42992466-6F4AA912-803A-4AFC-91B3-AC996BF260E2Q43000916-D7192E01-05D2-42DC-85DA-A253588B27E6Q43032202-0CA44E75-FB31-4768-B500-4B6DC9D4E82BQ43033457-47104D71-2894-4999-BE2F-069BEBE560AFQ43037633-CA525E55-E859-42AC-8EC4-49E38090FB77Q43039039-2FA4935B-AD65-4F36-9CC8-4CF15AE98C34Q43041030-A625F5DD-3C6D-4749-BF3B-8A1F5E09313BQ43041761-75F01394-5598-4E45-A20E-FA712211CC4CQ43047685-CC4104F9-70A4-48E2-BB82-D871DA2FC49EQ43048137-534C2861-FF2A-4250-BB3C-32C661AFA77DQ43048163-323085D1-63F9-4729-935B-508D2C32790DQ45364246-42BEADCD-59F8-408C-96EC-BEADBA88CE52Q45398019-769C48D2-8AE4-487E-BF51-85B0396B0B46Q45419512-877A2D52-20FA-4949-A26A-D7C28CA49BEE
P50
name
Pascale Trimoulet
@ast
Pascale Trimoulet
@en
Pascale Trimoulet
@es
Pascale Trimoulet
@nl
type
label
Pascale Trimoulet
@ast
Pascale Trimoulet
@en
Pascale Trimoulet
@es
Pascale Trimoulet
@nl
prefLabel
Pascale Trimoulet
@ast
Pascale Trimoulet
@en
Pascale Trimoulet
@es
Pascale Trimoulet
@nl